Prevalence and Risk Factors for HPV in HIV-Positive Young Women Receiving Their First HPV Vaccination.
ABSTRACT BACKGROUND:: The objectives of this study were to describe the prevalence and risk factors for HPV infection among HIV-infected young women receiving their first quadrivalent HPV (HPV-6, -11, -16, and -18) vaccine dose. METHODS:: We recruited 16- to 23-year-old women from 14 sites for an HPV vaccine trial. At the first visit, they completed a questionnaire and were tested for cervicovaginal HPV DNA (41 types) and HPV serology (4 vaccine types). Factors associated with any HPV, type-specific HPV, and high-risk (cancer-associated) HPV infections were identified using univariate and multivariable logistic regression. RESULTS:: The mean age of participants (N = 99) was 21.4 years, 30.3% were on antiretroviral therapy, 74.7% were positive for ≥1 HPV DNA type, 53.5% for ≥1 high-risk type, 12.1% for HPV-16, and 5.1% for HPV-18. Most were HPV DNA negative and seronegative for HPV-16 (55.6%) and HPV-18 (73.7%); 45.5% were HPV DNA negative and seronegative for both HPV-16 and -18. Three variables were associated with high-risk HPV DNA in multivariable analysis: non-Hispanic black versus Hispanic ethnicity (adjusted odds ratio [AOR]: 7.06, 95% CI: 1.63 to 30.5), HIV viral load ≥ 400 versus <400 copies/mL (AOR: 3.47, 95% CI: 1.28 to 9.43), and frequency of vaginal sex in the past 90 days (AOR: 5.82, 95% CI: 1.30 to 26.11 for ≥6 vs 0 times). CONCLUSIONS:: The prevalence of ≥1 HPV type was high in these young women, demonstrating the importance of vaccinating before sexual initiation. However, most women were HPV DNA negative and seronegative for high-risk vaccine-type HPV infection, supporting vaccination of sexually experienced HIV-positive young women.
[Show abstract] [Hide abstract]
ABSTRACT: Background. The objective of this study was to determine whether the 3-dose quadrivalent (HPV-6, -11, -16, -18) HPV vaccine series is immunogenic and safe in HIV-infected young women. Methods. We enrolled 99 16- to 23-year-old women in a phase II, open-label, multi-center trial, conducted from 2008-2011 by the Adolescent Trials Network for HIV/AIDS Interventions. Outcome measures were immunogenicity 4 weeks after dose 3, measured by 1) geometric mean titers (GMTs) and 2) seroconversion rates for HPV-6, -11, -16, and -18, among those seronegative and HPV DNA negative for each type. Immune responses were compared to those of a historical comparison group of HIV-negative women (N=267) using univariate methods. Clinical and laboratory adverse events were assessed after each dose. Results. The mean age of subjects was 21.4 years, 80% were Non-Hispanic Black, 69 were not taking antiretroviral therapy (ART) and 30 were taking ART. No differences in GMTs were noted among participants taking ART vs. the comparison group, but GMTs were lower in participants not taking ART vs. the comparison group for HPV-16 (2393 vs. 3892 mMU/mL, p=.012) and HPV-18 (463 mMU/mL vs. 801, p=.003). Seroconversion rates were 100% for HPV-6, -11, -16, and -18 among participants taking ART. Rates ranged from 92.3% (for HPV-18) to 100.0% (for HPV-6) among participants not taking ART. One severe adverse event (fatigue) was noted. Conclusions. In a sample of HIV-infected women who were HPV DNA and HPV seronegative, immune responses to HPV vaccination were generally robust and the vaccine was well-tolerated. Trial registration. NCT00710593.Clinical Infectious Diseases 05/2013; 57(5). DOI:10.1093/cid/cit319 · 9.42 Impact Factor